阿尔茨海默病血液生物标志物研究进展

连淑丽; 徐晶; 袁满琼; 方亚

doi:10.11847/zgggws1140159

阿尔茨海默病血液生物标志物研究进展

doi: 10.11847/zgggws1140159

厦门大学公共卫生学院卫生技术评估福建省高校重点实验室，福建厦门 361102

基金项目: 国家自然科学基金（81973144）

详细信息

作者简介:
连淑丽（1991 – ），女，福建漳州人，硕士在读，研究方向：老年认知健康

通讯作者:
方亚，E-mail：fangya@xmu.edu.cn

中图分类号: R 749.16
计量
- 文章访问数: 82
- HTML全文浏览量: 34
- PDF下载量: 20
- 被引次数: 0
出版历程
- 接收日期: 2022-08-29
- 网络出版日期: 2023-02-24
- 刊出日期: 2023-05-10

Blood-based biomarkers in Alzheimer′s disease: a review

School of Public Health, Xiamen University, Xiamen, Fujian Province 361102, China

摘要

摘要: 阿尔茨海默病（Alzheimer′s disease, AD）是一种起病隐匿的进行性发展的神经系统变性疾病，其病程长，疾病负担沉重，目前尚无治愈药物，但在早期阶段进行干预可延缓其病情进展，因此早期诊断对AD的防治尤为重要。脑脊液检测需要进行腰椎穿刺，侵入性强；而影像学检测价格昂贵且对设备要求高，因此这2种检测均无法作为AD高危人群大规模筛查手段进行推广。血液样本采集为微创伤性、快速、价格经济，且部分血液生物标志物在AD临床症状出现前即已发生显著变化，由此检测血液生物标志物可作为筛查AD早期患者的理想手段。本研究就AD的4种血液生物标志物，即β淀粉样蛋白（β-amyloid, Aβ）、Tau蛋白、β位点裂解酶1（beta-site APP cleaving enzyme 1, BACE1）、神经丝蛋白轻链（neurofilament light chain, NfL）及多标志物联合检测的近年的研究进展作一概述，以为AD的早期诊断、早干预、早治疗提供依据。
- 阿尔茨海默病 /
- 生物标志物 /
- β淀粉样蛋白 /
- Tau蛋白 /
- β位点裂解酶1 /
- 神经丝蛋白轻链
Abstract: Alzheimer′s disease (AD), as a neurodegenerative disease of the central nervous system, often progresses insidiously. AD is known to have long disease course and heavy disease burden and there is no cure for it currently. The proper intervention at an early stage has been proven effective to delay AD progression. Therefore, early diagnosis is critically important for the prevention and treatment of AD. Neither cerebrospinal fluid (CSF) detection nor imaging detection could be used as a screening tool for AD among high-risk population because of requirements for highly invasive operation or costly and specialized equipment. Minimal invasion, rapid collection, and affordable price make blood an ideal sample for AD screening. In this review, recent research advances in detections of four types of AD related blood-based biomarkers (amyloid-β protein, Tau protein, β-secretase 1, and neurofilament light chain) were summarized for providing a reference to relevant studies and clinical practice.
- Alzheimer′s disease /
- biomarker /
- amyloid-β protein /
- Tau protein /
- β-secretase 1 /
- neurofilament light chain

HTML全文

参考文献(65)

[1]	Alzheimer′s Disease International. World Alzheimer Report 2018: the state of the art of dementia research: new frontiers[EB/OL]. (2018 – 09 – 21)[2022 – 06 – 16]. https://www.alzint.org/reports-resources/page/7/.
[2]	王英全, 梁景宏, 贾瑞霞, 等. 2020 — 2050年中国阿尔茨海默病患病情况预测研究[J]. 阿尔茨海默病及相关病, 2019, 2(1): 289 – 298. doi: 10.3969/j.issn.2096-5516.2019.01.012
[3]	Wong W. Economic burden of Alzheimer disease and managed care considerations[J]. The American Journal of Managed Care, 2020, 26(S8): S177 – S183.
[4]	Jia JP, Wei CB, Chen SQ, et al. The cost of Alzheimer′s disease in China and re-estimation of costs worldwide[J]. Alzheimers′s and Dementia, 2018, 14(4): 483 – 491. doi: 10.1016/j.jalz.2017.12.006
[5]	McDade E, Bateman RJ. Stop Alzheimer′s before it starts[J]. Nature, 2017, 547(7662): 153 – 155. doi: 10.1038/547153a
[6]	Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer′s disease: towards clinical implementa-tion[J]. The Lancet Neurology, 2022, 21(1): 66 – 77. doi: 10.1016/S1474-4422(21)00361-6
[7]	Hampel H, O′Bryant SE, Molinuevo JL, et al. Blood-based bio-markers for Alzheimer disease: mapping the road to the clinic[J]. Nature Reviews Neurology, 2018, 14(11): 639 – 652. doi: 10.1038/s41582-018-0079-7
[8]	Leong YQ, Ng KY, Chye SM, et al. Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death[J]. Metabolic Brain Disease, 2020, 35(1): 11 – 30. doi: 10.1007/s11011-019-00516-y
[9]	Sharma P, Sharma A, Fayaz F, et al. Biological signatures of Alzheimer′s disease[J]. Current Topics in Medicinal Chemistry, 2020, 20(9): 770 – 781. doi: 10.2174/1568026620666200228095553
[10]	Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research frame-work: toward a biological definition of Alzheimer′s disease[J]. Alzheimer′s and Dementia, 2018, 14(4): 535 – 562. doi: 10.1016/j.jalz.2018.02.018
[11]	Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes[J]. Annals Neurology, 2018, 84(5): 648 – 658. doi: 10.1002/ana.25334
[12]	Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis[J]. Neurology, 2019, 93(17): e1647 – e1659. doi: 10.1212/WNL.0000000000008081
[13]	Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer′s disease[J]. EMBO Molecular Medicine, 2019, 11(12): e11170.
[14]	Castillo-Mendieta T, Arana-Lechuga Y, Campos-Peña V, et al. Plasma levels of amyloid-β peptides and tau protein in Mexican patients with Alzheimer′s disease[J]. Journal of Alzheimer′s Disease, 2021, 82(S1): S271 – S281. doi: 10.3233/JAD-200912
[15]	田金洲, 解恒革, 王鲁宁, 等. 中国阿尔茨海默病痴呆诊疗指南(2020年版)[J]. 中华老年医学杂志, 2021, 40(3): 269 – 283. doi: 10.3760/cma.j.issn.0254-9026.2021.03.001
[16]	Lövheim H, Elgh F, Johansson A, et al. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer′s disease[J]. Alzheimer′s and Dementia, 2017, 13(7): 778 – 782. doi: 10.1016/j.jalz.2016.12.004
[17]	Hsu JL, Lee WJ, Liao YC, et al. The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer′s disease[J]. Alzheimer′s Research and Therapy, 2017, 9(1): 91. doi: 10.1186/s13195-017-0319-x
[18]	Korecka M, Shaw LM. Mass spectrometry-based methods for robust measurement of Alzheimer′s disease biomarkers in biological fluids[J]. Journal of Neurochemistry, 2021, 159(2): 211 – 233. doi: 10.1111/jnc.15465
[19]	Pyun JM, Ryu JS, Lee R, et al. Plasma amyloid-β oligomerization tendency predicts amyloid PET positivity[J]. Clinical Interventions in Aging, 2021, 16: 749 – 755. doi: 10.2147/CIA.S312473
[20]	Meng X, Li T, Wang X, et al. Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer′s disease[J]. Alzheimer’s Research and Therapy, 2019, 11(1): 89. doi: 10.1186/s13195-019-0535-7
[21]	Chong FP, Ng KY, Koh RY, et al. Tau proteins and tauopathies in Alzheimer′s disease[J]. Cellular and Molecular Neurobiology, 2018, 38(5): 965 – 980. doi: 10.1007/s10571-017-0574-1
[22]	Sinsky J, Pichlerova K, Hanes J. Tau protein interaction partners and their roles in Alzheimer′s disease and other tauopathies[J]. International Journal of Molecular Sciences, 2021, 22(17): 9207. doi: 10.3390/ijms22179207
[23]	Ding XL, Zhang ST, Jiang LJ, et al. Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer′s disease: a systematic review and meta-analysis[J]. Translational Neurodegeneration, 2021, 10(1): 10. doi: 10.1186/s40035-021-00234-5
[24]	王雪莹, 李明, 卢志明. 阿尔茨海默病生物标志物应用指南及研究进展[J]. 中华预防医学杂志, 2022, 56(3): 262 – 269. doi: 10.3760/cma.j.cn112150-20210916-00902
[25]	Jagust WJ, Landau SM, Alzheimer′s Disease Neuroimaging Initiative. Temporal dynamics of β-amyloid accumulation in aging and Alzheimer disease[J]. Neurology, 2021, 96(9): e1347 – e1357. doi: 10.1212/WNL.0000000000011524
[26]	Sugarman MA, Zetterberg H, Blennow K, et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer′s disease[J]. Neurobiology of Aging, 2020, 94: 60 – 70. doi: 10.1016/j.neurobiolaging.2020.05.011
[27]	Shi YC, Lu X, Zhang LH, et al. Potential value of plasma amyloid-β, total tau, and neurofilament light for identification of early Alzheimer′s disease[J]. ACS Chemical Neuroscience, 2019, 10(8): 3479 – 3485. doi: 10.1021/acschemneuro.9b00095
[28]	Raket LL, Kühnel L, Schmidt E, et al. Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer′s disease[J]. Alzheimer′s and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12(1): e12099.
[29]	Jiao B, Liu H, Guo LN, et al. Performance of plasma amyloid β, total tau, and neurofilament light chain in the identification of probable Alzheimer′s disease in South China[J]. Frontiers in Aging Neuroscience, 2021, 13: 749649. doi: 10.3389/fnagi.2021.749649
[30]	Müller S, Preische O, Göpfert JC, et al. Tau plasma levels in subjective cognitive decline: results from the DELCODE study[J]. Scientific Reports, 2017, 7(1): 9529. doi: 10.1038/s41598-017-08779-0
[31]	Pase MP, Beiser AS, Himali JJ, et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes[J]. JAMA Neurology, 2019, 76(5): 598 – 606. doi: 10.1001/jamaneurol.2018.4666
[32]	Fossati S, Ramos Cejudo J, Debure L, et al. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer′s disease[J]. Alzheimer′s and Dementia:Diagnosis, Assessment and Disease Monitoring, 2019, 11(1): 483 – 492.
[33]	Barthélemy NR, Horie K, Sato C, et al. Blood plasma phosphory-lated-tau isoforms track CNS change in Alzheimer′s disease[J]. Journal of Experimental Medicine, 2020, 217(11): e20200861. doi: 10.1084/jem.20200861
[34]	Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer′s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study[J]. The Lancet Neurology, 2021, 20(9): 739 – 752. doi: 10.1016/S1474-4422(21)00214-3
[35]	Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer′s disease: a diagnostic perfor-mance and prediction modelling study using data from four prospec-tive cohorts[J]. The Lancet Neurology, 2020, 19(5): 422 – 433. doi: 10.1016/S1474-4422(20)30071-5
[36]	Clark C, Lewczuk P, Kornhuber J, et al. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer′s disease pathology and clinical disease progression[J]. Alzheimer′s Re-search and Therapy, 2021, 13(1): 65. doi: 10.1186/s13195-021-00805-8
[37]	Chen SD, Huang YY, Shen XN, et al. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer′s disease[J]. Translational Psychiatry, 2021, 11(1): 356. doi: 10.1038/s41398-021-01476-7
[38]	Hansson O, Cullen N, Zetterberg H, et al. Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease[J]. Annals of Clinical and Translational Neurology, 2021, 8(1): 259 – 265. doi: 10.1002/acn3.51253
[39]	Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer′s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzhei-mer′s dementia[J]. Nature Medicine, 2020, 26(3): 379 – 386. doi: 10.1038/s41591-020-0755-1
[40]	Cullen NC, Leuzy A, Palmqvist S, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations[J]. Nature Aging, 2021, 1(1): 114 – 123. doi: 10.1038/s43587-020-00003-5
[41]	Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neuro-degenerative disorders[J]. JAMA, 2020, 324(8): 772 – 781. doi: 10.1001/jama.2020.12134
[42]	Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer′s disease pathology[J]. Acta Neuropathologica, 2021, 141(5): 709 – 724. doi: 10.1007/s00401-021-02275-6
[43]	Cervellati C, Valacchi G, Zuliani G. Early elevation of BACE1 in dementia[J]. Aging, 2021, 13(22): 24480 – 24481. doi: 10.18632/aging.203727
[44]	Molinuevo JL, Ayton S, Batrla R, et al. Current state of Alzheimer′s fluid biomarkers[J]. Acta Neuropathologica, 2018, 136(6): 821 – 853. doi: 10.1007/s00401-018-1932-x
[45]	Shen Y, Wang HB, Sun QY, et al. Increased plasma beta-secretase 1 may predict conversion to Alzheimer′s disease dementia in indi-viduals with mild cognitive impairment[J]. Biological Psychiatry, 2018, 83(5): 447 – 455. doi: 10.1016/j.biopsych.2017.02.007
[46]	Cervellati C, Valacchi G, Zuliani G. BACE1: from biomarker to Alzheimer′s disease therapeutical target[J]. Aging, 2021, 13(9): 12299 – 12300. doi: 10.18632/aging.203064
[47]	Vakilian A, Masoumi J, Mirzaee S, et al. Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer′s disease[J]. Caspian Journal of Internal Medicine, 2019, 10(3): 276 – 280.
[48]	Vergallo A, Lemercier P, Cavedo E, et al. Plasma β-secretase1 concentrations correlate with basal forebrain atrophy and neuro-degeneration in cognitively healthy individuals at risk for AD[J]. Alzheimer’s and Dementia, 2021, 17(4): 629 – 640. doi: 10.1002/alz.12228
[49]	Zhang M, Zhong XM, Shi HS, et al. BACE1 and other Alzheimer′s-related biomarkers in cerebrospinal fluid and plasma distinguish Alzheimer′s disease patients from cognitively-impaired neuro-syphilis patients[J]. Journal of Alzheimer’s Disease, 2020, 77(1): 313 – 322. doi: 10.3233/JAD-200362
[50]	Neumann U, Ufer M, Jacobson LH, et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer′s disease[J]. EMBO Molecular Medicine, 2018, 10(11): e9316.
[51]	Hampel H, Vassar R, De Strooper B, et al. The β-secretase BACE1 in Alzheimer′s disease[J]. Biological Psychiatry, 2021, 89(8): 745 – 756. doi: 10.1016/j.biopsych.2020.02.001
[52]	Willemse EAJ, Scheltens P, Teunissen CE, et al. A neurologist′s perspective on serum neurofilament light in the memory clinic: a prospective implementation study[J]. Alzheimer′s Research and Therapy, 2021, 13(1): 101. doi: 10.1186/s13195-021-00841-4
[53]	Sánchez-Valle R, Heslegrave A, Foiani MS, et al. Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer′s disease[J]. Alzheimer’s Research and Therapy, 2018, 10(1): 113. doi: 10.1186/s13195-018-0439-y
[54]	Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration[J]. Neurology, 2017, 89(21): 2167 – 2175. doi: 10.1212/WNL.0000000000004667
[55]	Weston PSJ, Poole T, O′Connor A, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer′s disease[J]. Alzheimer′s Research and Therapy, 2019, 11(1): 19. doi: 10.1186/s13195-019-0472-5
[56]	Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer′s disease[J]. Nature Medicine, 2019, 25(2): 277 – 283. doi: 10.1038/s41591-018-0304-3
[57]	Andersson E, Janelidze S, Lampinen B, et al. Blood and cerebro-spinal fluid neurofilament light differentially detect neurodegenera-tion in early Alzheimer′s disease[J]. Neurobiology of Aging, 2020, 95: 143 – 153. doi: 10.1016/j.neurobiolaging.2020.07.018
[58]	Mattsson N, Cullen NC, Andreasson U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurology, 2019, 76(7): 791 – 799. doi: 10.1001/jamaneurol.2019.0765
[59]	van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study[J]. The Lancet Neurology, 2019, 18(12): 1103 – 1111. doi: 10.1016/S1474-4422(19)30354-0
[60]	Benussi A, Karikari TK, Ashton N, et al. Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁ in frontotemporal lobar degenera-tion[J]. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91(9): 960 – 967. doi: 10.1136/jnnp-2020-323487
[61]	Palmqvist S, Tideman P, Cullen N, et al. Prediction of future Alzheimer′s disease dementia using plasma phospho-tau combined with other accessible measures[J]. Nature Medicine, 2021, 27(6): 1034 – 1042. doi: 10.1038/s41591-021-01348-z
[62]	Pichet Binette A, Palmqvist S, Bali D, et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer′s dementia in mild cognitive impairment patients[J]. Alzheimer′s Research and Therapy, 2022, 14(1): 46. doi: 10.1186/s13195-022-00990-0
[63]	Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer′s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations[J]. Nature Communications, 2021, 12(1): 3555. doi: 10.1038/s41467-021-23746-0
[64]	Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status[J]. JAMA Neurology, 2019, 76(9): 1060 – 1069. doi: 10.1001/jamaneurol.2019.1632
[65]	Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer′s disease using combinations of plasma Aβ42/Aβ40 and p-tau[J]. Alzheimer′s and Dementia, 2022, 18(2): 283 – 293. doi: 10.1002/alz.12395